Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

NCT05132790 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: SHR-1316 at a dose 20mg/kg q3w
DRUG: SHR6390 at a dose of 150mg orally, daily
RADIATION: SBRT

Sponsor

Shengjing Hospital

Collaborators

[object Object]